Literature DB >> 8872495

Synergistic interaction between dehydroepiandrosterone and prednisolone in the inhibition of rat lymphocyte proliferation.

G M Meno-Tetang1, Y Y Hon, W J Jusko.   

Abstract

The interaction between dehydroepiandrosterone (DHEA) and prednisolone (PD) in the inhibition of rat lymphocyte proliferation was evaluated. The in vitro proliferative response of splenocytes from male Sprague-Dawley rats stimulated with phytohemagglutinin (PHA) was measured by the incorporation of 3H-thymidine into the DNA. DHEA and PD were added at the initiation of cultures individually and in various molar ratio combinations. The search for synergy, additivity or antagonism between the two compounds was performed by using the median-effect method of Chou and Talalay and Drewinko's statistical analysis. Both compounds individually inhibit the proliferation of PHA-stimulated rat lymphocytes. DHEA with an IC50 value of 13.4 microM was a thousand times less potent than PD which had an IC50 value of 5.4 nM. Synergy was observed between DHEA and PD. The intensity of the interaction appeared to be function of the molar ratio of the two drugs. The association of DHEA and PD could produce enhanced steroid effects in anti-inflammatory therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8872495     DOI: 10.3109/08923979609052746

Source DB:  PubMed          Journal:  Immunopharmacol Immunotoxicol        ISSN: 0892-3973            Impact factor:   2.730


  4 in total

1.  Pharmacokinetic and pharmacodynamic interactions between dehydroepiandrosterone and prednisolone in the rat.

Authors:  G M Meno-Tetang; Y Y Hon; S Van Wart; W J Jusko
Journal:  Drug Metabol Drug Interact       Date:  1999

Review 2.  Pharmacokinetic/pharmacodynamic modeling in inflammation.

Authors:  Hoi-Kei Lon; Dongyang Liu; William J Jusko
Journal:  Crit Rev Biomed Eng       Date:  2012

3.  Interactions of prednisolone and other immunosuppressants used in dual treatment of systemic lupus erythematosus in lymphocyte proliferation assays.

Authors:  Mohamed A Kamal; William J Jusko
Journal:  J Clin Pharmacol       Date:  2004-09       Impact factor: 3.126

4.  Interactions of everolimus and sorafenib in whole blood lymphocyte proliferation.

Authors:  Dipti K Pawaskar; Robert M Straubinger; Gerald J Fetterly; Wen W Ma; William J Jusko
Journal:  Pharm Res       Date:  2012-11-14       Impact factor: 4.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.